Orange Book product · Brand (NDA)
TIROSINT
LEVOTHYROXINE SODIUM
At a glance
Apr 25, 2017
Approved
Brand (NDA)
Application
Not listed
TE code
1
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Apr 25, 2017
9 yr 3 mo ago
Today
Patent 12564565 expires
Listed drug product patent expiration.
Sep 26, 2044
in 18 yr 6 mo
Pharmaceutical detail
Active ingredient
LEVOTHYROXINE SODIUM
Strength
0.2MG
Dosage form
CAPSULE
Route
ORAL
TE code
Not listed
Application
NDA 021924
Product number
012
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2022ERMEZABrand (NDA)
NDA 215809 · MYLAN
- 2021LEVOTHYROXINE SODIUMBrand (NDA)
NDA 214253 · HIKMA
- 2020THYQUIDITYBrand (NDA)
NDA 214047 · STEVENS J
- 2019LEVOTHYROXINE SODIUMBrand (NDA)
NDA 210632 · FRESENIUS KABI USA
- 2016TIROSINT-SOLBrand (NDA)
NDA 206977 · IBSA
- 2011LEVOTHYROXINE SODIUMBrand (NDA)
NDA 202231 · FRESENIUS KABI USA
- 2003LEVOLETBrand (NDA)
NDA 021137 · GENUS LIFESCIENCES
- 2002THYRO-TABSBrand (NDA)
NDA 021116 · ALVOGEN
- 2002SYNTHROIDBrand (NDA)
NDA 021402 · ABBVIE
- 2002EUTHYROXBrand (NDA)
NDA 021292 · EMD SERONO INC
- 2002LEVO-TBrand (NDA)
NDA 021342 · CEDIPROF INC
- 2001LEVOXYLBrand (NDA)
NDA 021301 · KING PHARMS
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 12564565 | Sep 26, 2044 | in 18 yr 6 mo | Product |

